Methods of treating heavy menstrual bleeding
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
1. A method of managing heavy menstrual bleeding associated with uterine fibroids in a premenopausal adult human female patient, the method comprising:
once daily oral administration of a first capsule to the patient, said first capsule comprising (i) 300 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, administered as a sodium salt (“elagolix”), (ii) 1.0 mg of estradiol, and (iii) 0.5 mg of norethindrone acetate; and
once daily oral administration of a second capsule to the patient, said second capsule comprising 300 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, administered as a sodium salt;
wherein the first and second capsules are administered in approximately the morning and evening of each day, respectively;
wherein said administration of the first and second capsules continues for a time period as needed to manage the heavy menstrual bleeding associated with uterine fibroids; and
wherein the method is effective to manage the heavy menstrual bleeding associated with uterine fibroids while limiting bone mineral density loss from baseline in the patient caused by exposure to elagolix to less than 8% following 24 weeks of said once daily oral administration of the first and second capsule.
2. A method of managing heavy menstrual bleeding associated with uterine fibroids in a premenopausal adult human female patient, the method comprising:
once daily oral administration of a first dose to the patient, said first dose comprising (i) 300 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, administered as a sodium salt (“elagolix”), (ii) 1.0 mg of estradiol, and (iii) 0.5 mg of norethindrone acetate; and
once daily oral administration of a second dose to the patient, said second dose comprising 300 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, administered as a sodium salt;
wherein the first and second doses are administered in approximately the morning and evening of each day, respectively;
wherein said administration of the first and second doses continues for a time period as needed to manage the heavy menstrual bleeding associated with uterine fibroids; and
wherein the method is effective to manage the heavy menstrual bleeding associated with uterine fibroids while limiting bone mineral density loss from baseline in the patient caused by exposure to elagolix to less than 8% following 24 weeks of said once daily oral administration of the first and second dose.
3. The method of claim 2 , wherein the first dose comprises a capsule containing at least the estradiol and norethindrone acetate.
4. The method of claim 2 , wherein the second dose comprises a capsule containing elagolix.
5. The method of claim 2 , wherein the first dose comprises a capsule containing elagolix, estradiol, and norethindrone acetate.
6. The method of claim 5 , wherein the second dose comprises a capsule containing elagolix.